Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
87.81
+0.70 (0.80%)
At close: Jun 27, 2025, 4:00 PM
87.81
0.00 (0.00%)
After-hours: Jun 27, 2025, 7:00 PM EDT
Alcon Revenue
Alcon had revenue of $2.47B in the quarter ending March 31, 2025, with 0.57% growth. This brings the company's revenue in the last twelve months to $9.93B, up 3.80% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm)
$9.93B
Revenue Growth
+3.80%
P/S Ratio
4.40
Revenue / Employee
$387,710
Employees
25,599
Market Cap
43.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ALC News
- 1 day ago - Alcon Canada Earns Global Recognition as a Top Employer - Business Wire
- 2 days ago - Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System - GlobeNewsWire
- 7 days ago - Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Business Wire
- 24 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Business Wire
- 4 weeks ago - US FDA approves Alcon's new dry-eye drug - Reuters
- 4 weeks ago - Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - Business Wire
- 4 weeks ago - Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - GlobeNewsWire
- 6 weeks ago - Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript - Seeking Alpha